
Vertex Pharmaceuticals’ cystic fibrosis therapy Alyftrek granted EC approval
Vertex Pharmaceuticals’ cystic fibrosis (CF) therapy Alyftrek (deutivacaftor/tezacaftor/vanzacaftor) has been approved by the European Commission (EC). The triple combination treatment has been specifically authorised for use in CF patients aged …